Schumer/Waxman Call For Industry Groups To Condemn Generic Drug Payoffs
This article was originally published in The Pink Sheet Daily
Executive Summary
In letters to PhRMA and GPhA, legislators point to FTC report detailing industry settlements as a sign of growing anti-competitive activity.
You may also be interested in...
Supreme Court Denies Certiorari To FTC v. Schering-Plough
The high court denies the Federal Trade Commission’s petition to hear the case regarding issues raised by brand companies’ reverse payments to generic firms.
Supreme Court Denies Certiorari To FTC v. Schering-Plough
The high court denies the Federal Trade Commission’s petition to hear the case regarding issues raised by brand companies’ reverse payments to generic firms.
Unsettling Settlements: FTC Alarmed By Increasing Brand/Generic Deals
The Federal Trade Commission notes the threat of authorized generics, as well as its appeals court loss in the K-Dur case, as reasons for the jump in settlements.